Eyeworld

22 | EYEWORLD BONUS ISSUE | FEBRUARY 2025 G UCOMA Contact Brubaker: jbrubaker@saceye.com Williamson: blakewilliamson@weceye.com References 1. Berdahl JP, et al. Efficacy and safety of the travoprost intraoc- ular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hyperten- sion. Drugs. 2023;84:83–97. 2. Medeiros FA, et al. Phase 3, randomized, 20-month study of bimatoprost implant in open-an- gle glaucoma and ocular hyper- tension (ARTEMIS 1). Ophthal- mology. 2020;127:1627–1641. 3. Teymoorian S, et al. Real- world study of the effectiveness and safety of intracameral bimatoprost implant in a clinical setting in the United States. Clin Ophthalmol. 2024;18:187–199. Relevant disclosures Brubaker: AbbVie, Alcon, Glaukos Williamson: AbbVie, Glaukos platform for glaucoma (GLK-302) in Phase 2 trials. Takeaways When it comes to sustained-release options, Dr. Williamson said you have to be honest with yourself and with your patients about the like- lihood (or rather the unlikelihood) that they're taking the medications exactly the way that you're prescribing them. "If you know that to be true, you just have to admit that by putting them on a second or third bottle of eye drops, you're not doing right by the patient. You're not doing anything wrong, you're not breaching standard of care, but you're not doing the best for your patient," he said. "Do you really trust that they're going to take that second or third bottle of medica- tion appropriately? Once you admit that they're not going to be 100% compliant, you have to think, 'What can I do that is extremely safe but also gives good efficacy and would reduce or eliminate needing to give new medications to my glaucoma patients?' That's when you look at the two [sustained-release] options that we have now." Dr. Williamson said that Durysta has a short learning curve and can be done in the OR or at the slit lamp. He advised those just starting out to place it in the OR in a pseudophakic patient to gain comfort with the procedure before po- tentially moving on to slit lamp placement with a phakic patient. For iDose TR, he said if you've placed an iStent, especially iStent infinite, then the iDose TR procedure is very similar. continued from page 21 Intraoperative view of iDose TR in the left eye of a patient Source: Jacob Brubaker, MD Durysta in the inferior angle of the left eye with a previously placed iStent inject (Glaukos) Source: Jacob Brubaker, MD Read more! Gain additional perspectives on adoption and pearls for new drug delivery options in the extended online version of this article.

• Cover